Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
Fiche publication
Date publication
mai 2023
Journal
Journal of experimental & clinical cancer research : CR
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
Tous les auteurs :
Liu J, Zhang R, Su T, Zhou Q, Gao L, He Z, Wang X, Zhao J, Xing Y, Sun F, Cai W, Wang X, Han J, Qin R, Désaubry L, Han B, Chen W
Lien Pubmed
Résumé
Castration-resistant prostate cancer (CRPC) is currently the main challenge for prostate cancer (PCa) treatment, and there is an urgent need to find novel therapeutic targets and drugs. Prohibitin (PHB1) is a multifunctional chaperone/scaffold protein that is upregulated in various cancers and plays a pro-cancer role. FL3 is a synthetic flavagline drug that inhibits cancer cell proliferation by targeting PHB1. However, the biological functions of PHB1 in CRPC and the effect of FL3 on CRPC cells remain to be explored.
Mots clés
CRPC, Enzalutamide, FL3, Prohibitin
Référence
J Exp Clin Cancer Res. 2023 05 20;42(1):128